49.92 0.00 (0.00%)
After hours: 4:00PM EST
|Bid||49.94 x 800|
|Ask||49.98 x 1000|
|Day's Range||48.60 - 50.53|
|52 Week Range||37.01 - 51.05|
|Beta (5Y Monthly)||1.23|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 25, 2020 - Mar 2, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||58.91|
Reblozyl Studies Evaluating Treatment of Anemia in Rare Blood Diseases Presented at American Society of Hematology (ASH) Annual Meeting
Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today the appointment of Jay T. Backstrom, M.D., M.P.H., as Executive Vice President, Research and Development (R&D). Dr. Backstrom joins Acceleron from Celgene Corporation, where he most recently served as Chief Medical Officer (CMO).
Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Our research shows that most of the stocks that smart money likes historically generate strong […]
Bristol-Myers Squibb and Acceleron Pharma Provide Update on FDA Advisory Committee for Reblozyl® (luspatercept-aamt)
Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today the appointment of Kemal Malik, MB BS, to its Board of Directors. Dr. Malik, who is currently a member of the Board of Management of Bayer AG, will officially join the Acceleron Board effective January 1, 2020.
Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today that it has been included in the recently released Institutional Investor 2020 "All-America Executive Team" rankings as one of the country’s "Most Honored" companies.
Bristol-Myers (BMY) and Acceleron Pharma Inc.'s sBLA for Reblozyl in patients with myelodysplastic syndromes will be reviewed by the FDA's Oncologic Drugs Advisory Committee.
A Relative Strength Rating upgrade for Acceleron Pharma shows improving technical performance. Will it continue?
Bristol-Myers Squibb Company (BMY) and Acceleron Pharma Inc. (XLRN) today announced the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee will hold a review of Bristol-Myers Squibb’s supplemental Biologics License Application (sBLA) for the use of Reblozyl® (luspatercept-aamt) in patients with myelodysplastic syndromes (MDS) at its meeting on December 18, 2019. Bristol-Myers Squibb is seeking approval of Reblozyl, an erythroid maturation agent representing a new class of therapy, for the treatment of adult patients with very low- to intermediate-risk MDS-associated anemia who have ring sideroblasts and require red blood cell (RBC) transfusions.
Acceleron Pharma Inc. today announced it will host a webcast and conference call on Tuesday, December 10, 2019 at 6:00 a.m. EST to review highlights from its presentations at the 61st American Society of Hematology Annual Meeting & Exposition in Orlando, Florida, on December 7-10, 2019.
Geron's (GERN) telomerase inhibitor, imetelstat, is being evaluated in two clinical studies for patients with MDS and myelofibrosis. The candidate is progressing well in clinical studies.
CRISPR Therapeutics and Vertex Pharmaceuticals released the first data from their early-stage trial testing the safety and effectiveness of a potential cure for the genetic blood disorders sickle cell disease and beta thalassemia.
Celgene (CELG) and partner Acceleron obtain FDA approval for Reblozyl for the treatment of anemia in adult patients with beta thalassemia.
Shares of Acceleron Pharma popped Friday after the biotech company gained Food and Drug Administration approval for a Celgene-partnered anemia treatment in patients with beta thalassemia.
Shares of Celgene Corp. [s:celg] rose 0.34% in afternoon trading after the U.S. Food and Drug Administration approved Reblozyl. The drug, which treats anemia in patients with beta thalassemia, a rare blood disorder, was developed jointly by the drugmaker and Acceleron Pharma Inc. . It's the first FDA-approved therapy for Acceleron. Acceleron shares were up about 6% to $43.17. Bristol-Myers Squibb 's acquisition of Celgene for $74 billion in cash and stock is expected to close by the end of the year. Celgene's stock is up roughly 70% year to date, while the S&P Index has gained 23% this year.
Luspatercept is one of the first treatments for beta thalassemia, a blood disorder being targeted by multiple local companies.
REBLOZYL is the first and only FDA-approved erythroid maturation agent, representing a new class of therapy for these patients
Acceleron (XLRN) delivered earnings and revenue surprises of -6.17% and 22.11%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
– Updated results from MEDALIST Phase 3 trial show 47.1% of patients with anemia associated with myelodysplastic syndromes treated with luspatercept achieved red blood cell transfu
Acceleron (XLRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.